Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Krahl, A."'
Autor:
Christian Jakob, Christian Junghanss, Sebastian Schwind, Volker Schmidt, Niklas Zojer, Kolija Reifenrath, Andreas Hochhaus, Christoph Kahl, Dietger Niederwieser, Haifa Kathrin Al-Ali, Georg Maschmeyer, Thomas Heinicke, Herbert G. Sayer, Norma Peter, Rainer Krahl, Thomas Fischer, Sebastian Scholl, Axel Florschütz, Ute Hegenbart, Michael Cross, Hans-Heinrich Wolf, Christian Niederwieser
Publikováno v:
Blood. 134:1358-1358
Introduction: Outcome of patients (pts) with refractory AML or following relapse is considered dismal and usually reported as refractory/relapsed. Here we analyzed long term outcome of refractory and relapsing pts separately over a 10 year (y) period
Autor:
Dietger Niederwieser, Thomas Friedrich, Michael W. Deininger, Christina Franke, Evelin Hennig, Thomas Bumm, Erika Schmidt, Knut Krohn, Patricia Shepherd, Christel Müller, R. Krahl, Sabine Leiblein, Haifa Kathrin Al-Ali
Publikováno v:
Blood. 101:1941-1949
Chronic myelogenous leukemia (CML) is characterized by the presence of a Bcr-Abl fusion protein with deregulated tyrosine kinase activity that is required for maintaining the malignant phenotype. Imatinib, a selective inhibitor ofBcr-Abl, induces maj
Autor:
Mathias Haenel, Song-Yau Wang, Susann Schultze, Nadja Jaekel, Christian Jakob, Regina Herbst, Georg Maschmeyer, Dietger Niederwieser, Oana Brosteanu, Haifa Kathrin Al-Ali, Rainer Krahl, Karolin Hubert
Publikováno v:
Blood. 126:1346-1346
The prognosis of AML in patients (pts) >60 years (y) is poor and there is no universally accepted standard approach. After induction chemotherapy (IC), a complete remission (CR+CRi) rate of 56.4% and a mortality of 21% at day (d) 90 are expected (Nie
Autor:
Haifa Kathrin Al-Ali, Thomas Heinicke, Herbert G. Sayer, Hans-Heinrich Wolf, Kolja Reifenrath, Christian Junghanss, Sebastian Scholl, Rainer Krahl, Norma Peter, Thomas Fischer, Antje Schulze, Niklas Zojer, Christian Jakob, Georg Maschmeyer, Christoph Kahl, Ute Hegenbart, Axel Florschütz, Andreas Hochhaus, Dietger Niederwieser, Detlev Hähling
Publikováno v:
Blood. 124:3666-3666
Purpose: To define prognostic factors for overall survival in adult patients (pts) with relapsed acute myeloid leukemia (AML). Introduction: Prognostic factors for overall survival after AML relapse are poorly defined. Here, we investigate patient an
Autor:
Nadja Jaekel, Cornelia Becker, Leanthe Braunert, Thoralf Lange, Rainer Krahl, Georg Franke, Dietger Niederwieser, Jeanett Edelmann, Wolfram Poenisch, Sabine Leiblein, Claudia Nehring, Haifa Kathrin Al-Ali
Publikováno v:
Blood. 118:3065-3065
Abstract 3065 Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity-conditioning (RIC) is a curative therapeutic option in elderly patients with AML. Yet, hematological relapse (HR) and non-relapse mortality (NRM) remain maj
Autor:
Gert J. Ossenkoppele, Vladan Vucinic, Marc Boogaerts, Georg Franke, Alois Gratwohl, Norma Peter, Michael Cross, Mathias Freund, Jan J. Cornelissen, Haifa Kathrin Al-Ali, Bob Löwenberg, Gottfried Doelken, Rainer Krahl, Dietger Niederwieser, Leo F. Verdonck, Harry C. Schouten, Thoralf Lange, Georg Maschmeyer
Publikováno v:
Blood. 118:2030-2030
Abstract 2030 HSCT after reduced or minimal intensity conditioning is increasingly used to treat AML patients not eligible for conventional HSCT. Short term outcome has been reported frequently and risk factors have been identified; long term results
Autor:
Uwe G. Liebert, Haifa Kathrin Al-Ali, Rainer Krahl, Marianne Hehme, Mark Westerman, Sabine Leiblein, Ann-Kathrin Eisfeld, Dietger Niederwieser
Publikováno v:
Blood. 114:4047-4047
Abstract 4047 Poster Board III-982 Hepcidin (hep), a 25-amino-acid peptide, is the central regulator of iron homeostasis. Its transcription is upregulated by inflammatory cytokines and iron and is downregulated by iron deficiency, ineffective erythro
Autor:
Cornelia Becker, Ute Kreibich, Christian Junghanß, Rainer Krahl, Erika Kettner, Mathias Haenel, Hans-Heinrich Wolf, Thomas Ittel, Antje Schulze, Dietrich Kaempfe, Renate Huhn, Georg Maschmeyer, W. Helbig, Axel Florschuetz, Bernd Opitz, Dietger Niederwieser, Michael Assmann, Ulrich Wedding, Dirk Hasenclever, Ernst Zschuppe, Veronika Schirmer, Astrid Franke, Wolfram Poenisch, Mathias Schulze, Norbert Grobe, Norma Peter, Johannes G. Meran, Detlev Haehling, Gottfried Doelken
Publikováno v:
Blood. 112:2966-2966
Clinical trials on different cytarabine doses for treatment of AML provide evidence of a dose response effect, but also for increase toxicity after high dose AraC (HDAC). Pharmacokinetic measurements of cytarabine-triphosphate (AraC-CTP), which is th
Autor:
Dietger Niederwieser, Oliver Pelz-Ackermann, Michael W. Deininger, Michael Cross, Haifa Kathrin Al-Ali, Rainer Krahl, Song-Yau Wang, Kathrin Wildenberger, Thoralf Lange
Publikováno v:
Blood. 110:2918-2918
Objectives: Acquired resistance to imatinib (IM) in patients with chronic myeloid leukaemia (CML) is frequently due to mutations of the BCR-ABL kinase domain (KD). Current thinking holds that this results from the selection of pre-existing mutant clo
Autor:
Arnold Ganser, Gerhard Ehninger, Brigitte Schlegelberger, Claus Meyer, Markus Schaich, Jürgen Krauter, Hartmut Döhner, Cristina Sauerland, Dietger Niederwieser, Konstanze Döhner, Rolf Marschalek, Katharina Wagner, Irina Schäfer, Richard F. Schlenk, Gerhard Heil, Thomas Büchner, Rainer Krahl
Publikováno v:
Blood. 110:759-759
The MLL gene on chromosome 11q23 is translocated to a variety of fusion partners in about 5–10% of adults with acute myeloid leukemia (AML). The heterogeneity of these genetic aberrations hampers risk stratification of the patients. To identify pro